Safety and Efficacy of Autologous or Donor-derived CD19 CAR-T Treatment in Relapsed B Acute Lymphocytic Leukemia after Allo-HSCT

被引：0

作者：

Zhang, Xian ^{[1
]}

Lu, Xin-An ^{[2
]}

Xiong, Min ^{[1
]}

Yang, Jun-Fang ^{[1
]}

Zhang, Jian-Ping ^{[1
]}

Zhou, Xiao-Su ^{[1
]}

He, Ting ^{[2
]}

Lu, Pei-Hua ^{[1
]}

机构：

[1] Hebei Yanda Ludaopei Hosp, Langfang, Peoples R China

[2] Immuno China Pharmaceut Co Ltd, Beijing, Peoples R China

来源：

BONE MARROW TRANSPLANTATION | 2018年 / 53卷

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

O144

引用

页码：122 / 123

页数：2

共 50 条

[21] Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant
Cao, Xing-yu
Zhang, Jian-Ping
Zhao, Yan-Li
Xiong, Min
Zhou, Jiarui
Lu, Yue
Sun, Ruijuan
Wei, Zhijie
Liu, Deyan
Zhang, Xian
Yang, Junfang
Lu, Peihua
BLOOD, 2022, 140 : 4802 - 4803
[22] Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Wenjie Li
Lixia Ding
Wenhua Shi
Xinyu Wan
Xiaomin Yang
Jing Yang
Tianyi Wang
Lili Song
Xiang Wang
Yani Ma
Chengjuan Luo
Jingyan Tang
Longjun Gu
Jing Chen
Jun Lu
Yanjing Tang
Benshang Li
Journal of Translational Medicine, 21
[23] Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Li, Wenjie
Ding, Lixia
Shi, Wenhua
Wan, Xinyu
Yang, Xiaomin
Yang, Jing
Wang, Tianyi
Song, Lili
Wang, Xiang
Ma, Yani
Luo, Chengjuan
Tang, Jingyan
Gu, Longjun
Chen, Jing
Lu, Jun
Tang, Yanjing
Li, Benshang
JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
[24] Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
Yang, Tingting
Dong, Yetian
Zhang, Mingming
Feng, Jingjing
Fu, Shan
Xiao, Pingnan
Hong, Ruimin
Xu, Huijun
Cui, Jiazhen
Huang, Simao
Wei, Guoqing
Chang, Alex H.
Huang, He
Hu, Yongxian
BLOOD, 2024, 144 : 2819 - 2819
[25] Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia
Yang, Tingting
Dong, Yetian
Zhang, Mingming
Feng, Jingjing
Fu, Shan
Xiao, Pingnan
Hong, Ruimin
Xu, Huijun
Cui, Jiazhen
Huang, Simao
Wei, Guoqing
Kong, Delin
Geng, Jia
Chang, Alex H.
Huang, He
Hu, Yongxian
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2025, 14 (01)
[26] Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT "Sandwich" Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia
Qiu, Yan
Qian, Chong-Sheng
Zhou, Hai-Xia
Xu, Ming-Zhu
Kang, Li-Qing
Sun, Ai-Ning
Wu, De-Pei
Yu, Lei
Xue, Sheng-Li
BLOOD, 2023, 142
[27] Good Survival of CAR-T Cell Therapy Bridging to Allo-HSCT for Relapsed/Refractory Ph-Positive B-Cell Acute Lymphoblastic Leukemia
Liu, Zhanxiang
Wu, Tong
Song, Yanzhi
Yuan, Erhui
Qin, Qishu
Wang, Qi
BLOOD, 2023, 142
[28] Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation
Li, Yingying
Li, Yixue
Zhang, Mingming
Zhao, Houli
Zhu, Miaoyong
Huang, He
Hu, Yongxian
EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (01) : 94 - 101
[29] Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT
Yang, Yingying
Hu, Yongxian
Huang, He
REGENERATIVE THERAPY, 2019, 11 : 139 - 142
[30] Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
Li, Xin
Liu, Mei-Jing
Mou, Nan
Yang, Zhen-Xing
Wang, Jia
Mu, Juan
Zhu, Hai-Bo
Deng, Qi
ONCOLOGY LETTERS, 2021, 22 (05)

← 1 2 3 4 5 →